Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Hebei Senlang Biotechnology Co., Ltd.
organization2 mentionslast seen Nov 12, 2026
Clinical-stage cell therapy company focused on next-generation CAR-T technologies with specialized expertise in CD7-targeted CAR-T development.
Relationships 3
- Hebei Senlang Biotechnology Co., Ltd.developsCD7-targeted lentiviral vector platform99% confidence2 sources
- Tempest Therapeutics, Inc.partners withHebei Senlang Biotechnology Co., Ltd.99% confidence2 sources
- Hebei Senlang Biotechnology Co., Ltd.developsBCMA/GPRC5D dual-targeting in vivo CAR-T95% confidence1 source
Relationship
Hebei Senlang Biotechnology Co., Ltd.developsCD7-targeted lentiviral vector platform
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 12, 2026Tempest Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Senlang's CD7-targeted lentiviral vector platform
- filingSEC EDGARSep 17, 2026Tempest Therapeutics, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
Senlang's proprietary platform uses targeted lentiviral vectors to deliver CAR transgenes